Fount of Information

Toronto Research Chemicals社 Covid-19 Research Targets I R&D tools


Dear Researcher,
The coronavirus outbreak has now been labelled a pandemic by WHO. There are currently no antiviral drugs licensed by the FDA to treat patients from COVID-19. Remdesivir was reported to have in-vitro activity against SARS-CoV-2 and is now in the clinical trial phase. Researchers across the globe are working on the development of candidate vaccines and therapeutics for an effective antiviral molecule. In this newsletter, we are showcasing some of our product categories which are helpful in the R&D of antiviral therapies and can be an essential tool to aid the researchers.

We hope that you find this newsletter to be a valuable source of information.

        Bromodomain Inhibitors

I-BET 151

Catalog No: I120050

  • Part of a novel series of quinoline isoxazole BET family bromodomain inhibitors, a family of four proteins that selectively bind to acetylated lysine residues in histone


        Remdesivir Metabolite

Remdesivir Carboxylic Acid

Catalog No: R530520

  • A metabolite of Remdesivir (CAS#:1809249-37-3); small molecule GS-​5734 with therapeutic efficacy against Ebola virus in rhesus monkeys.


        Abl Kinase Inhibitors


Catalog No: B820020

  • An inhibitor of c-Abl and Bcr-abl activity
  • Primarily used for Phosphorylation & Dephosphorylation applications.


         RdRp Inhibitors

BCX 4430

Catalog No: B119190

  • An adenosine analog developed by BioCryst Pharma.
  • Potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease.


        OSBP Inhibitors


Catalog No: I937500

  • Itraconazole is an antifungal and inhibitor of hedgehog signalling


        Endosomal pH Regulators

SN 7618

Catalog No: C379965

  • Substrate for MRP in multidrug-resistant cell line and inhibits photoaffinity labelling of MRP by quinoline-based photoactive drug IAAQ.



Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。